BioPharma Credit PLC
BOPCF
Other OTC1.01
USD
+0.03
- -
ISIN
GB00BDGKMY29
CUSIP
G12808104
Return %
Stock
S&P500
1Y
18.82
19.01
3Y
16.09
65.48
5Y
3.38
72.20
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- Pedro Gonzalez de Cosio
- Sector
- Financial Services
- Industry
- Asset Management
- Address
- 51 New North Road London GL United Kingdom EC3M 7DQ
- IPO Date
- Aug 21, 2018
- Website
- bpcruk.com
- Similar Companies
- Business
- BioPharma Credit PLC is a United Kingdom-based specialist debt investor to the life sciences industry, providing investors access to debt capital and delivering long-term shareholder returns through sustainable income distributions. The company primarily invests in a diversified portfolio of debt assets secured by royalties or other cash flows derived from sales of approved life sciences products, including loans and other instruments; it may also invest in equity issued by life sciences companies either directly or in the secondary market. BioPharma Credit operates globally with a focus on the fast-growing life sciences sector and holds the majority of its investments through its wholly owned financing subsidiary, BPCR Limited Partnership. Founded in 2016 and headquartered in Exeter, UK, the company is managed by Pharmakon Advisors, LP, which brings extensive industry expertise and access to a broad range of investment opportunities. Recent major developments include a senior secured loan agreement entered in October 2025 with Valneva and BioPharma-V and the initiation of an equity buyback plan representing approximately 14.99% of its issued share capital, reflecting strategic capital management moves. The company targets an annual dividend yield of 7% and aims for a net total return on net asset value of 8-9% per annum in the medium term, underscoring its commitment to predictable income generation for shareholders. BioPharma Credit also expanded its portfolio with a commitment to a new investment of up to US$62.5 million in parallel with BioPharma-V, reinforcing its position as a key debt capital provider in the life sciences domain. BioPharma Credit PLC's product offerings are centered on tailored financing solutions secured by life sciences product royalties, supplemented by strategic equity positions to foster portfolio diversification and risk mitigation. It maintains two wholly owned subsidiaries: BPCR Limited Partnership and BPCR GP Limited, facilitating its investment activities and operational structure.
BioPharma Credit PLC (OTCMKTS:BOPCF) Short Interest Up 75.0% in December